Search

Your search keyword '"Färkkilä, Anniina"' showing total 323 results
Start Over Author "Färkkilä, Anniina"
323 results on '"Färkkilä, Anniina"'

2. Tracing back primed resistance in cancer via sister cells

Author

Dai, Jun, Zheng, Shuyu, Falco, Matías M., Bao, Jie, Eriksson, Johanna, Pikkusaari, Sanna, Forstén, Sofia, Jiang, Jing, Wang, Wenyu, Gao, Luping, Perez-Villatoro, Fernando, Dufva, Olli, Saeed, Khalid, Wang, Yinyin, Amiryousefi, Ali, Färkkilä, Anniina, Mustjoki, Satu, Kauppi, Liisa, Tang, Jing, and Vähärautio, Anna

Published
2024
Full Text
View/download PDF

3. Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer

Author

Launonen, Inga-Maria, Niemiec, Iga, Hincapié-Otero, María, Erkan, Erdogan Pekcan, Junquera, Ada, Afenteva, Daria, Falco, Matias M., Liang, Zhihan, Salko, Matilda, Chamchougia, Foteini, Szabo, Angela, Perez-Villatoro, Fernando, Li, Yilin, Micoli, Giulia, Nagaraj, Ashwini, Haltia, Ulla-Maija, Kahelin, Essi, Oikkonen, Jaana, Hynninen, Johanna, Virtanen, Anni, Nirmal, Ajit J., Vallius, Tuulia, Hautaniemi, Sampsa, Sorger, Peter K., Vähärautio, Anna, and Färkkilä, Anniina

Published
2024
Full Text
View/download PDF

5. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.

Author

Zhou, Jia, Gelot, Camille, Pantelidou, Constantia, Li, Adam, Yücel, Hatice, Davis, Rachel, Färkkilä, Anniina, Kochupurakkal, Bose, Syed, Aleem, Shapiro, Geoffrey, Tainer, John, Blagg, Brian, Ceccaldi, Raphael, and DAndrea, Alan

Subjects
Fanconi Anemia, HRD cancer, Homologous Recombination, MMEJ, Novobiocin, PARP inhibitor resistance, Polymerase theta (POLθ), Adenosine Triphosphatases, Female, Homologous Recombination, Humans, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors
Abstract

DNA polymerase theta (POLθ) is synthetic lethal with Homologous Recombination (HR) deficiency and thus a candidate target for HR-deficient cancers. Through high-throughput small molecule screens we identified the antibiotic Novobiocin (NVB) as a specific POLθ inhibitor that selectively kills HR-deficient tumor cells in vitro and in vivo. NVB directly binds to the POLθ ATPase domain, inhibits its ATPase activity, and phenocopies POLθ depletion. NVB kills HR-deficient breast and ovarian tumors in GEMM, xenograft and PDX models. Increased POLθ levels predict NVB sensitivity, and BRCA-deficient tumor cells with acquired resistance to PARP inhibitors (PARPi) are sensitive to NVB in vitro and in vivo. Mechanistically, NVB-mediated cell death in PARPi-resistant cells arises from increased double-strand break end resection, leading to accumulation of single-strand DNA intermediates and non-functional RAD51 foci. Our results demonstrate that NVB may be useful alone or in combination with PARPi in treating HR-deficient tumors, including those with acquired PARPi resistance. (151/150).

Published
2021

6. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

Author

Konstantinopoulos, Panagiotis A., Cheng, Su-Chun, Lee, Elizabeth K., da Costa, Alexandre André B.A., Gulhan, Doga, Wahner Hendrickson, Andrea E., Kochupurakkal, Bose, Kolin, David L., Kohn, Elise C., Liu, Joyce F., Penson, Richard T., Stover, Elizabeth H., Curtis, Jennifer, Sawyer, Hannah, Polak, Madeline, Chowdhury, Dipanjan, DʼAndrea, Alan D., Färkkilä, Anniina, Shapiro, Geoffrey I., and Matulonis, Ursula A.

Published
2024
Full Text
View/download PDF

8. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation

Author

Duraiswamy, Jaikumar, Turrini, Riccardo, Minasyan, Aspram, Barras, David, Crespo, Isaac, Grimm, Alizée J., Casado, Julia, Genolet, Raphael, Benedetti, Fabrizio, Wicky, Alexandre, Ioannidou, Kalliopi, Castro, Wilson, Neal, Christopher, Moriot, Amandine, Renaud-Tissot, Stéphanie, Anstett, Victor, Fahr, Noémie, Tanyi, Janos L., Eiva, Monika A., Jacobson, Connor A., Montone, Kathleen T., Westergaard, Marie Christine Wulff, Svane, Inge Marie, Kandalaft, Lana E., Delorenzi, Mauro, Sorger, Peter K., Färkkilä, Anniina, Michielin, Olivier, Zoete, Vincent, Carmona, Santiago J., Foukas, Periklis G., Powell, Daniel J., Jr., Rusakiewicz, Sylvie, Doucey, Marie-Agnès, Dangaj Laniti, Denarda, and Coukos, George

Published
2021
Full Text
View/download PDF

9. Inhibition of TGFβ1 and TGFβ3 promotes hematopoiesis in Fanconi anemia

Author

Rodríguez, Alfredo, Yang, Chunyu, Furutani, Elissa, García de Teresa, Benilde, Velázquez, Martha, Filiatrault, Jessica, Sambel, Larissa A., Phan, Tin, Flores-Guzmán, Patricia, Sánchez, Silvia, Monsiváis Orozco, Angélica, Mayani, Héctor, Bolukbasi, Ozge V., Färkkilä, Anniina, Epperly, Michael, Greenberger, Joel, Shimamura, Akiko, Frías, Sara, Grompe, Markus, Parmar, Kalindi, and D'Andrea, Alan D.

Published
2021
Full Text
View/download PDF

10. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Author

Konstantinopoulos, Panagiotis A, Cheng, Su-Chun, Wahner Hendrickson, Andrea E, Penson, Richard T, Schumer, Susan T, Doyle, L Austin, Lee, Elizabeth K, Kohn, Elise C, Duska, Linda R, Crispens, Marta A, Olawaiye, Alexander B, Winer, Ira S, Barroilhet, Lisa M, Fu, Siqing, McHale, Michael T, Schilder, Russell J, Färkkilä, Anniina, Chowdhury, Dipanjan, Curtis, Jennifer, Quinn, Roxanne S, Bowes, Brittany, D'Andrea, Alan D, Shapiro, Geoffrey I, and Matulonis, Ursula A

Published
2020
Full Text
View/download PDF

13. Abstract A080: CD8+T-cell interplay with myeloid cells as spatial determinant of chemotherapy response in the tumor microenvironment of metastatic high-grade serous ovarian cancer

Author

Launonen, Inga-Maria P., primary, Erkan, Erdogan P., additional, Niemiec, Iga, additional, Mencía, Ada Junquera, additional, Szabo, Angela, additional, Perez, Fernando, additional, Kahelin, Essi, additional, Hautaniemi, Sampsa, additional, Oikkonen, Jaana, additional, Hynninen, Johanna, additional, Virtanen, Anni, additional, Vallius, Tuulia, additional, Nirmal, Ajit J., additional, Sorger, Peter, additional, Vähärautio, Anna, additional, and Färkkilä, Anniina, additional

Published
2024
Full Text
View/download PDF

14. Abstract PR-007: Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous ovarian cancer

Author

Färkkilä, Anniina, primary, Nagaraj, Ashwini S., additional, Pietilä, Elina A., additional, Salko, Matilda, additional, Erkan, Erdogan P., additional, Niemiec, Iga, additional, Sirsikar, Aditi, additional, Bao, Jie, additional, Marchi, Giovanni, additional, Nowlan, Kirsten, additional, Hautaniemi, Sampsa, additional, Vähärautio, Anna, additional, Tang, Jing, additional, Haltia, Ulla-Maija, additional, Kekäläinen, Eliisa, additional, Virtanen, Anni, additional, and Salo, Tuula, additional

Published
2024
Full Text
View/download PDF

15. Abstract B060: Spatial landscape of cell cycle dynamics post-neoadjuvant chemotherapy in high-grade serous ovarian carcinoma

Author

Junquera, Ada, primary, Liang, Zhihan, additional, Niemiec, Iga, additional, Launonen, Inga-Maria, additional, Luna-Alvarez, Mariana, additional, Salko, Matilda, additional, Vääriskoski, Maija, additional, Kahelin, Essi, additional, Haltia, Ulla-Maija, additional, Virtanen, Anni, additional, and Färkkilä, Anniina, additional

Published
2024
Full Text
View/download PDF

16. Abstract B073: A spatially resolved single-cell tumor microenvironment of clinicomolecular subtypes of high-grade serous ovarian cancer

Author

Perez-Villatoro, Fernando, primary, van Wagensveld, Lilian, additional, Shabanova, Aleksandra, additional, Hajizadeh, Siamak, additional, Casado, Julia, additional, Anttila, Ella, additional, van der Aa, Maaike A., additional, Kruitwagen, Roy F.P.M., additional, Sonke, Gabe S., additional, Van de Vijver, Koen K., additional, Sorger, Peter K., additional, Horlings, Hugo M., additional, and Färkkilä, Anniina, additional

Published
2024
Full Text
View/download PDF

17. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Author

Konstantinopoulos, Panagiotis A., da Costa, Alexandre André B. A., Gulhan, Doga, Lee, Elizabeth K., Cheng, Su-Chun, Hendrickson, Andrea E. Wahner, Kochupurakkal, Bose, Kolin, David L., Kohn, Elise C., Liu, Joyce F., Stover, Elizabeth H., Curtis, Jennifer, Tayob, Nabihah, Polak, Madeline, Chowdhury, Dipanjan, Matulonis, Ursula A., Färkkilä, Anniina, D’Andrea, Alan D., and Shapiro, Geoffrey I.

Published
2021
Full Text
View/download PDF

19. TERT promoter mutation in adult granulosa cell tumor of the ovary

Author

Pilsworth, Jessica A., Cochrane, Dawn R., Xia, Zhouchunyang, Aubert, Geraldine, Färkkilä, Anniina E.M., Horlings, Hugo M., Yanagida, Satoshi, Yang, Winnie, Lim, Jamie L.P., Wang, Yi Kan, Bashashati, Ali, Keul, Jacqueline, Wong, Adele, Norris, Kevin, Brucker, Sara Y., Taran, Florin-Andrei, Krämer, Bernhard, Staebler, Annette, van Meurs, Hannah, Oliva, Esther, Shah, Sohrab P., Kommoss, Stefan, Kommoss, Friedrich, Gilks, C. Blake, Baird, Duncan M., and Huntsman, David G.

Published
2018
Full Text
View/download PDF

21. Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Author

Pikkusaari, Sanna, primary, Tumiati, Manuela, primary, Virtanen, Anni, primary, Oikkonen, Jaana, primary, Li, Yilin, primary, Perez-Villatoro, Fernando, primary, Muranen, Taru, primary, Salko, Matilda, primary, Huhtinen, Kaisa, primary, Kanerva, Anna, primary, Koskela, Heidi, primary, Tapper, Johanna, primary, Koivisto-Korander, Riitta, primary, Joutsiniemi, Titta, primary, Haltia, Ulla-Maija, primary, Lassus, Heini, primary, Hautaniemi, Sampsa, primary, Färkkilä, Anniina, primary, Hynninen, Johanna, primary, Hietanen, Sakari, primary, Carpén, Olli, primary, and Kauppi, Liisa, primary

Published
2023
Full Text
View/download PDF

22. Figure 5 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Author

Pikkusaari, Sanna, primary, Tumiati, Manuela, primary, Virtanen, Anni, primary, Oikkonen, Jaana, primary, Li, Yilin, primary, Perez-Villatoro, Fernando, primary, Muranen, Taru, primary, Salko, Matilda, primary, Huhtinen, Kaisa, primary, Kanerva, Anna, primary, Koskela, Heidi, primary, Tapper, Johanna, primary, Koivisto-Korander, Riitta, primary, Joutsiniemi, Titta, primary, Haltia, Ulla-Maija, primary, Lassus, Heini, primary, Hautaniemi, Sampsa, primary, Färkkilä, Anniina, primary, Hynninen, Johanna, primary, Hietanen, Sakari, primary, Carpén, Olli, primary, and Kauppi, Liisa, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure S7 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Author

Pikkusaari, Sanna, primary, Tumiati, Manuela, primary, Virtanen, Anni, primary, Oikkonen, Jaana, primary, Li, Yilin, primary, Perez-Villatoro, Fernando, primary, Muranen, Taru, primary, Salko, Matilda, primary, Huhtinen, Kaisa, primary, Kanerva, Anna, primary, Koskela, Heidi, primary, Tapper, Johanna, primary, Koivisto-Korander, Riitta, primary, Joutsiniemi, Titta, primary, Haltia, Ulla-Maija, primary, Lassus, Heini, primary, Hautaniemi, Sampsa, primary, Färkkilä, Anniina, primary, Hynninen, Johanna, primary, Hietanen, Sakari, primary, Carpén, Olli, primary, and Kauppi, Liisa, primary

Published
2023
Full Text
View/download PDF

24. Table 1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Author

Pikkusaari, Sanna, primary, Tumiati, Manuela, primary, Virtanen, Anni, primary, Oikkonen, Jaana, primary, Li, Yilin, primary, Perez-Villatoro, Fernando, primary, Muranen, Taru, primary, Salko, Matilda, primary, Huhtinen, Kaisa, primary, Kanerva, Anna, primary, Koskela, Heidi, primary, Tapper, Johanna, primary, Koivisto-Korander, Riitta, primary, Joutsiniemi, Titta, primary, Haltia, Ulla-Maija, primary, Lassus, Heini, primary, Hautaniemi, Sampsa, primary, Färkkilä, Anniina, primary, Hynninen, Johanna, primary, Hietanen, Sakari, primary, Carpén, Olli, primary, and Kauppi, Liisa, primary

Published
2023
Full Text
View/download PDF

25. Figure 3 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Author

Pikkusaari, Sanna, primary, Tumiati, Manuela, primary, Virtanen, Anni, primary, Oikkonen, Jaana, primary, Li, Yilin, primary, Perez-Villatoro, Fernando, primary, Muranen, Taru, primary, Salko, Matilda, primary, Huhtinen, Kaisa, primary, Kanerva, Anna, primary, Koskela, Heidi, primary, Tapper, Johanna, primary, Koivisto-Korander, Riitta, primary, Joutsiniemi, Titta, primary, Haltia, Ulla-Maija, primary, Lassus, Heini, primary, Hautaniemi, Sampsa, primary, Färkkilä, Anniina, primary, Hynninen, Johanna, primary, Hietanen, Sakari, primary, Carpén, Olli, primary, and Kauppi, Liisa, primary

Published
2023
Full Text
View/download PDF

26. Figure 1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Author

Pikkusaari, Sanna, primary, Tumiati, Manuela, primary, Virtanen, Anni, primary, Oikkonen, Jaana, primary, Li, Yilin, primary, Perez-Villatoro, Fernando, primary, Muranen, Taru, primary, Salko, Matilda, primary, Huhtinen, Kaisa, primary, Kanerva, Anna, primary, Koskela, Heidi, primary, Tapper, Johanna, primary, Koivisto-Korander, Riitta, primary, Joutsiniemi, Titta, primary, Haltia, Ulla-Maija, primary, Lassus, Heini, primary, Hautaniemi, Sampsa, primary, Färkkilä, Anniina, primary, Hynninen, Johanna, primary, Hietanen, Sakari, primary, Carpén, Olli, primary, and Kauppi, Liisa, primary

Published
2023
Full Text
View/download PDF

27. Data from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Author

Pikkusaari, Sanna, primary, Tumiati, Manuela, primary, Virtanen, Anni, primary, Oikkonen, Jaana, primary, Li, Yilin, primary, Perez-Villatoro, Fernando, primary, Muranen, Taru, primary, Salko, Matilda, primary, Huhtinen, Kaisa, primary, Kanerva, Anna, primary, Koskela, Heidi, primary, Tapper, Johanna, primary, Koivisto-Korander, Riitta, primary, Joutsiniemi, Titta, primary, Haltia, Ulla-Maija, primary, Lassus, Heini, primary, Hautaniemi, Sampsa, primary, Färkkilä, Anniina, primary, Hynninen, Johanna, primary, Hietanen, Sakari, primary, Carpén, Olli, primary, and Kauppi, Liisa, primary

Published
2023
Full Text
View/download PDF

28. Figure 4 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Author

Pikkusaari, Sanna, primary, Tumiati, Manuela, primary, Virtanen, Anni, primary, Oikkonen, Jaana, primary, Li, Yilin, primary, Perez-Villatoro, Fernando, primary, Muranen, Taru, primary, Salko, Matilda, primary, Huhtinen, Kaisa, primary, Kanerva, Anna, primary, Koskela, Heidi, primary, Tapper, Johanna, primary, Koivisto-Korander, Riitta, primary, Joutsiniemi, Titta, primary, Haltia, Ulla-Maija, primary, Lassus, Heini, primary, Hautaniemi, Sampsa, primary, Färkkilä, Anniina, primary, Hynninen, Johanna, primary, Hietanen, Sakari, primary, Carpén, Olli, primary, and Kauppi, Liisa, primary

Published
2023
Full Text
View/download PDF

29. Figure 2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Author

Pikkusaari, Sanna, primary, Tumiati, Manuela, primary, Virtanen, Anni, primary, Oikkonen, Jaana, primary, Li, Yilin, primary, Perez-Villatoro, Fernando, primary, Muranen, Taru, primary, Salko, Matilda, primary, Huhtinen, Kaisa, primary, Kanerva, Anna, primary, Koskela, Heidi, primary, Tapper, Johanna, primary, Koivisto-Korander, Riitta, primary, Joutsiniemi, Titta, primary, Haltia, Ulla-Maija, primary, Lassus, Heini, primary, Hautaniemi, Sampsa, primary, Färkkilä, Anniina, primary, Hynninen, Johanna, primary, Hietanen, Sakari, primary, Carpén, Olli, primary, and Kauppi, Liisa, primary

Published
2023
Full Text
View/download PDF

31. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells

Author

Haltia, Ulla-Maija, Andersson, Noora, Yadav, Bhagwan, Färkkilä, Anniina, Kulesskiy, Evgeny, Kankainen, Matti, Tang, Jing, Bützow, Ralf, Riska, Annika, Leminen, Arto, Heikinheimo, Markku, Kallioniemi, Olli, Unkila-Kallio, Leila, Wennerberg, Krister, Aittokallio, Tero, and Anttonen, Mikko

Published
2017
Full Text
View/download PDF

33. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Author

Färkkilä, Anniina, Gulhan, Doga C., Casado, Julia, Jacobson, Connor A., Nguyen, Huy, Kochupurakkal, Bose, Maliga, Zoltan, Yapp, Clarence, Chen, Yu-An, Schapiro, Denis, Zhou, Yinghui, Graham, Julie R., Dezube, Bruce J., Munster, Pamela, Santagata, Sandro, Garcia, Elizabeth, Rodig, Scott, Lako, Ana, Chowdhury, Dipanjan, Shapiro, Geoffrey I., Matulonis, Ursula A., Park, Peter J., Hautaniemi, Sampsa, Sorger, Peter K., Swisher, Elizabeth M., D’Andrea, Alan D., and Konstantinopoulos, Panagiotis A.

Published
2020
Full Text
View/download PDF

34. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Author

Färkkilä, Anniina, Gulhan, Doga C., Casado, Julia, Jacobson, Connor A., Nguyen, Huy, Kochupurakkal, Bose, Maliga, Zoltan, Yapp, Clarence, Chen, Yu-An, Schapiro, Denis, Zhou, Yinghui, Graham, Julie R., Dezube, Bruce J., Munster, Pamela, Santagata, Sandro, Garcia, Elizabeth, Rodig, Scott, Lako, Ana, Chowdhury, Dipanjan, Shapiro, Geoffrey I., Matulonis, Ursula A., Park, Peter J., Hautaniemi, Sampsa, Sorger, Peter K., Swisher, Elizabeth M., D’Andrea, Alan D., and Konstantinopoulos, Panagiotis A.

Published
2020
Full Text
View/download PDF

40. Data from Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer

Author

Chae, Chang-Suk, primary, Sandoval, Tito A., primary, Hwang, Sung-Min, primary, Park, Eun Sil, primary, Giovanelli, Paolo, primary, Awasthi, Deepika, primary, Salvagno, Camilla, primary, Emmanuelli, Alexander, primary, Tan, Chen, primary, Chaudhary, Vidyanath, primary, Casado, Julia, primary, Kossenkov, Andrew V., primary, Song, Minkyung, primary, Barrat, Franck J., primary, Holcomb, Kevin, primary, Romero-Sandoval, E. Alfonso, primary, Zamarin, Dmitriy, primary, Pépin, David, primary, D'Andrea, Alan D., primary, Färkkilä, Anniina, primary, and Cubillos-Ruiz, Juan R., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure from Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer

Author

Chae, Chang-Suk, primary, Sandoval, Tito A., primary, Hwang, Sung-Min, primary, Park, Eun Sil, primary, Giovanelli, Paolo, primary, Awasthi, Deepika, primary, Salvagno, Camilla, primary, Emmanuelli, Alexander, primary, Tan, Chen, primary, Chaudhary, Vidyanath, primary, Casado, Julia, primary, Kossenkov, Andrew V., primary, Song, Minkyung, primary, Barrat, Franck J., primary, Holcomb, Kevin, primary, Romero-Sandoval, E. Alfonso, primary, Zamarin, Dmitriy, primary, Pépin, David, primary, D'Andrea, Alan D., primary, Färkkilä, Anniina, primary, and Cubillos-Ruiz, Juan R., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 1 from Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells

Author

Färkkilä, Anniina, primary, Rodríguez, Alfredo, primary, Oikkonen, Jaana, primary, Gulhan, Doga C., primary, Nguyen, Huy, primary, Domínguez, Julieta, primary, Ramos, Sandra, primary, Mills, Caitlin E., primary, Pérez-Villatoro, Fernando, primary, Lazaro, Jean-Bernard, primary, Zhou, Jia, primary, Clairmont, Connor S., primary, Moreau, Lisa A., primary, Park, Peter J., primary, Sorger, Peter K., primary, Hautaniemi, Sampsa, primary, Frias, Sara, primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

45. Figure S3 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Author

Parmar, Kalindi, primary, Kochupurakkal, Bose S., primary, Lazaro, Jean-Bernard, primary, Wang, Zhigang C., primary, Palakurthi, Sangeetha, primary, Kirschmeier, Paul T., primary, Yang, Chunyu, primary, Sambel, Larissa A., primary, Färkkilä, Anniina, primary, Reznichenko, Elizaveta, primary, Reavis, Hunter D., primary, Dunn, Connor E., primary, Zou, Lee, primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, D'Andrea, Alan D., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Data from Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells

Author

Färkkilä, Anniina, primary, Rodríguez, Alfredo, primary, Oikkonen, Jaana, primary, Gulhan, Doga C., primary, Nguyen, Huy, primary, Domínguez, Julieta, primary, Ramos, Sandra, primary, Mills, Caitlin E., primary, Pérez-Villatoro, Fernando, primary, Lazaro, Jean-Bernard, primary, Zhou, Jia, primary, Clairmont, Connor S., primary, Moreau, Lisa A., primary, Park, Peter J., primary, Sorger, Peter K., primary, Hautaniemi, Sampsa, primary, Frias, Sara, primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

49. Data from Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells

Author

Färkkilä, Anniina, primary, Rodríguez, Alfredo, primary, Oikkonen, Jaana, primary, Gulhan, Doga C., primary, Nguyen, Huy, primary, Domínguez, Julieta, primary, Ramos, Sandra, primary, Mills, Caitlin E., primary, Pérez-Villatoro, Fernando, primary, Lazaro, Jean-Bernard, primary, Zhou, Jia, primary, Clairmont, Connor S., primary, Moreau, Lisa A., primary, Park, Peter J., primary, Sorger, Peter K., primary, Hautaniemi, Sampsa, primary, Frias, Sara, primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table S1 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Author

Parmar, Kalindi, primary, Kochupurakkal, Bose S., primary, Lazaro, Jean-Bernard, primary, Wang, Zhigang C., primary, Palakurthi, Sangeetha, primary, Kirschmeier, Paul T., primary, Yang, Chunyu, primary, Sambel, Larissa A., primary, Färkkilä, Anniina, primary, Reznichenko, Elizaveta, primary, Reavis, Hunter D., primary, Dunn, Connor E., primary, Zou, Lee, primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, D'Andrea, Alan D., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results